Your fact-checks will appear here
Nonprofit organization in Schaumburg, United States
Two registered early‑phase clinical trials combine ivermectin with immune checkpoint inhibitors for cancer: a phase I/II investigator‑initiated trial testing oral ivermectin with balstilimab (and an e...
Clinical testing of ivermectin as a cancer therapy is very limited and largely early-phase: the clearest ongoing human study is a phase I/II trial combining ivermectin with the PD‑1 agent balstilimab ...
Only a single actively registered randomized or early-phase trial of ivermectin in human cancer patients is clearly documented in the available reporting: a phase I/II study combining oral ivermectin ...
Clinical investigation of ivermectin in human cancer patients is extremely limited: the only clearly documented clinical trial testing ivermectin in cancer patients is a phase I/II study for metastati...
Two U.S.-registered trials testing ivermectin in cancer patients are identifiable in recent reporting: a Phase I/II study combining ivermectin with the PD‑1 agonist balstilimab for metastatic triple‑n...
There are very few registered clinical trials testing ivermectin in cancer: the clearest active, publicly listed study is NCT05318469 (a phase I/II trial combining oral ivermectin with anti‑PD‑1 immun...
Two registered clinical studies testing ivermectin in cancer exist and are at early phase stages; most detailed public reporting centers on a Phase I/II trial (NCT05318469) combining ivermectin with t...
Clinical research testing ivermectin in cancer patients in 2024–2025 is sparse and concentrated mainly on triple‑negative breast cancer (TNBC) immunotherapy combinations; multiple reviews and preclini...
There is evidence of a small number of early‑phase clinical trials testing ivermectin in cancer patients, but they are limited in number, mostly based in the United States, and focused on combination ...
As of 2025, ClinicalTrials.gov shows a single registered interventional study testing ivermectin for cancer: a Phase I/II trial (NCT05318469) combining oral ivermectin with an immune checkpoint inhibi...
A single, actively recruiting clinical program testing ivermectin together with immune checkpoint blockade in cancer patients has emerged in the published record: a Phase I/II trial (ClinicalTrials.go...
The only published outcome from the ivermectin + immunotherapy TNBC effort tied to ClinicalTrials.gov identifier NCT05318469 through the end of 2025 is an ASCO 2025 meeting abstract reporting safety a...
Clinical human data on ivermectin as an anticancer therapy are very limited: most evidence is preclinical (cell lines and animal models) showing antiproliferative, pro‑apoptotic and immune‑modulating ...